Cubist Systematic Strategies, LLC Cardiff Oncology, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.22 - $5.89 $80,899 - $214,637	36,441 Added 112.86%	68,730 $152,000
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $47,141 - $190,827	32,289 New	32,289 $172,000
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $80,835 - $180,324	-69,090 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.11 - $7.25 $125,838 - $432,382	59,639 Added 631.03%	69,090 $171,000
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $84,086 - $117,526	-16,233 Reduced 63.2%	9,451 $57,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $108,516 - $164,182	-21,660 Reduced 45.75%	25,684 $171,000
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $297,115 - $448,577	-44,679 Reduced 48.55%	47,344 $315,000
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $230,539 - $495,786	25,334 Added 37.99%	92,023 $852,000
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $801,601 - $1.65 Million	66,689 New	66,689 $1.2 Million

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $175M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.